Get the weekly note

Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.

ETFIQetfiq.com · independent ETF data

VTI vs XBI: how they differ

VTI and XBI hold 2% of their weight in the same names, and XBI returned more over the year.

Vanguard Total Stock Market Index Fund and State Street(R) SPDR(R) S&P(R) Biotech ETF.

What they hold in common

By the books each fund has filed, VTI and XBI hold 2% of their money in the same securities at the same weight.

Positions VTI and XBI both hold, largest shared weight first
HoldingVTIXBI
AbbVie Inc0.62%1.04%
Amgen Inc0.27%1.00%
Gilead Sciences Inc0.22%0.97%
Vertex Pharmaceuticals Inc0.17%1.06%
Regeneron Pharmaceuticals Inc0.09%0.96%
Alnylam Pharmaceuticals Inc0.06%0.96%
REVOLUTION Medicines Inc0.05%1.21%
Natera Inc0.05%1.17%
Biogen Inc0.04%1.03%
Moderna Inc0.04%1.41%
Insmed Inc0.03%1.08%
United Therapeutics Corp0.03%0.93%
Largest positions each one holds and the other does not
Only in VTIOnly in XBI
NVIDIA Corp 6.37%Roivant Sciences Ltd 1.16%
Apple Inc 5.88%Alkermes PLC 1.11%
Microsoft Corp 3.84%uniQure NV 1.03%
Amazon.com Inc 3.19%CRISPR Therapeutics AG 1.02%
Alphabet Inc 2.90%Biohaven Ltd 0.53%
Broadcom Inc 2.48%Hyperliquid Strategies Inc 0.47%
Alphabet Inc 2.29%Damora Therapeutics Inc 0.17%
Micron Technology Inc 1.80%Prothena Corp PLC 0.13%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.

VTI and XBI on the fields both publish, as of Sep 12, 2026. Source: ETFIQ.
VTI
Vanguard Total Stock Market Index Fund
XBI
State Street(R) SPDR(R) S&P(R) Biotech ETF
Where it sitsCore index fundCore index fund
IssuerVanguardState Street
What it isUS total marketSPDR S&P Biotech
Total return, 1 year+17.2%+64.0%
S&P 500 over the same days+17.5%+17.5%
Gap to the S&P 500−0.3 pts+46.5 pts
Expense ratio0.03%0.35%
Already in the S&P 50088.3%8.5%
Holdings3531150

VTI in plain words

VTI is an index equity fund tracking the US total market. Over the year to Sep 11, 2026 it returned +17.2% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.03% a year. By its holdings filed for Jun 30, 2026, 88% of the fund by weight is stocks the S&P 500 also holds, across 3531 positions, with the top ten at 32.1%.

XBI in plain words

XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.

Questions people ask

Which returned more over the last year, VTI or XBI?
In the year to Sep 12, 2026, with distributions reinvested, VTI returned +17.2% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
Which is cheaper, VTI or XBI?
VTI charges 0.03% a year and XBI charges 0.35%, so VTI is cheaper. Fees come from each fund's prospectus.
How much do VTI and XBI overlap with the S&P 500?
By their latest filed holdings, 88% of VTI and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 2% of their books are the same securities at the same weight.

Other comparisons

Where to next

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

VTI against XBI, ETFIQ, data as of Sep 12, 2026. Every figure is arithmetic on a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, VTI against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/VTI-XBI Free to use with attribution; the underlying files are at Open data.

A comparison is not a recommendation. Standards and sources